Abbisko Therapeutics
Abbisko Therapeutics has 1 licensing announcement in this dataset, dated 2023-12-01.
- Country / operating region
- China
- Ticker
- 查無
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.abbisko.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| pimicotinib (ABSK021) | CSF-1R | small molecule | 查無 | 2023-12-01 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| pimicotinib (ABSK021) | Phase III (at source date) | — | 查無 | 查無 | 2024-02-06 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2023-12-01 | Merck KGaA, Darmstadt, Germany | pimicotinib (ABSK021) | USD 70m | 查無 | 查無 | ≤ USD 605.5m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Merck KGaA, Darmstadt, Germany | Mainland China, Hong Kong, Macau and Taiwan; option for global commercial rights | Double-digit percentage royalties on annual net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無